Research News

Novartis has announced compelling Phase III results for GanLum (ganaplacide/lumefantrine, KLU156), a next-generation antimalarial developed with Medicines for Malaria Venture (MMV). The combination therapy achieved a 97.4% PCR-corrected cure rate in the KALUMA study marking a major advancement in malaria treatment amid rising drug resistance across Africa.

A new Advocacy Paper, developed by leading nephrology experts of the country, outlines a roadmap to scale peritoneal dialysis - a simple, home-based treatment for kidney failure across India, ensuring equitable access to treatment for kidney failure, especially for rural and marginalised communities.

A tailored approach of vitamin D3 supplementation in patients who have suffered a heart attack significantly reduces their risk of a second heart attack, a new study from heart researchers at Intermountain Health in Salt Lake City finds.

In a historic leap for global health, an international team of scientists has developed the world’s first genetically engineered, product-ready snake antivenom — a potential game-changer for treating bites from some of Africa’s most lethal snakes, including cobras, mambas, and rinkhals.

Semaglutide significantly reduced major adverse cardiovascular events in patients with overweight or obesity with cardiovascular disease but without diabetes, as per recent research study conducted by University College London.

A multiple sclerosis patient in the UK was the first to receive CAR T cell therapy, invented by UCL researchers, in a clinical trial testing whether this personalised treatment can slow or even halt the progression of the disease.

Addressing the question of whether and how immune cells in the central nervous system traffic out, researchers have now identified a perineural pathway through which the HIV virus can redistribute throughout the body.

An international clinical study led by the Medical University of Vienna shows that the drug patritumab deruxtecan (HER3-DXd) can have a promising effect in patients with active brain metastases of various tumour types.

Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the Phase 3 ACHIEVE-2 and ACHIEVE-5 trials. ACHIEVE-2, the second head-to-head trial in the program, evaluated orforglipron versus dapagliflozin, an SGLT-2 inhibitor, in adults with type 2 diabetes inadequately controlled on metformin.